Type 2 myocardial infarction and myocardial injury: eligibility for novel medical therapy to derisk clinical trials

BACKGROUND: Patients with type 2 myocardial infarction (T2MI) and other mechanisms of nonthrombotic myocardial injury have an unmet therapeutic need. Eligibility for novel medical therapy is generally uncertain. METHODS: We predefined colchicine, eplerenone and ticagrelor as candidates for repurposi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sykes, Robert, Briscoe, Michael, Krysztofiak, Thomas, Peck, Oliver, Mangion, Kenneth, Berry, Colin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Coronary Artery Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8174491/
https://www.ncbi.nlm.nih.gov/pubmed/34083388
http://dx.doi.org/10.1136/openhrt-2021-001633

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8174491/
https://www.ncbi.nlm.nih.gov/pubmed/34083388
http://dx.doi.org/10.1136/openhrt-2021-001633

Ejemplares similares